Evidence map›Paper›PMID 34205470›Full record

ArticleInternational journal of molecular sciences2021

The Transplantation Resistance of Type II Diabetes Mellitus Adipose-Derived Stem Cells Is Due to G6PC and IGF1 Genes Related to the FoxO Signaling Pathway.

Michiko Horiguchi, Yuya Turudome, Kentaro Ushijima

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Frontiers in pharmacology · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michiko HoriguchiDivision of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, 1-1-1 Daigaku-Dori, Sanyo Onoda 756-0884, Japan.ORCID 0000-0003-0670-3738
Yuya TurudomeDivision of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, 1-1-1 Daigaku-Dori, Sanyo Onoda 756-0884, Japan.
Kentaro UshijimaDivision of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, 1-1-1 Daigaku-Dori, Sanyo Onoda 756-0884, Japan.
Sanyo-Onoda City University · JP

Funding

Japan Society for the Promotion of Science 19K23802Japan Society for the Promotion of Science 20K20590Naito Foundation 2019-2021
6 · The paper itself

Abstract

In cases of patients with rapidly progressive diabetes mellitus (DM), autologous stem cell transplantation is considered as one of the regenerative treatments. However, whether the effects of autonomous stem cell transplantation on DM patients are equivalent to transplantation of stem cells derived from healthy persons is unclear. This study revealed that adipose-derived mesenchymal stem cells (ADSC) derived from type II DM patients had lower transplantation efficiency, proliferation potency, and stemness than those derived from healthy persons, leading to a tendency to induce apoptotic cell death. To address this issue, we conducted a cyclopedic mRNA analysis using a next-generation sequencer and identified

Indexed as

Mesenchymal Stem Cell TransplantationCells, CulturedDiabetes Mellitus, Type 2Glucose-6-PhosphataseHumansInsulin-Like Growth Factor IMesenchymal Stem CellsSignal TransductionTransplantation, AutologousG6PC3 protein, humanGlucose-6-PhosphataseIGF1 protein, humanInsulin-Like Growth Factor Iadipose-derived mesenchymal stem cells (ADSC)FoxO signaling pathwayG6PC3IGF1stem celltransplant resistancetype II diabetes mellitus

Identifiers

PMID34205470
PMCPMC8235161
OpenAlexW3173507470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.